Amantadine in cancer fatigue
Phase 3
- Conditions
- Fatigue due to cancer.
- Registration Number
- IRCT20181208041882N10
- Lead Sponsor
- Yazd University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Cancer patients who complain of fatigue as a side effect of treatment
Patients currently on a chemotherapy regimen are at risk for fatigue
Exclusion Criteria
Patients with a hemoglobin level of less than 10 g / dl
Patients with a white blood cell count of less than 3,000 cells / mcl
Patients with a platelet count less than 10,000 cells / mcl
Patients with a serum creatinine greater than 2 mg / dl
Patients whose bilirubin level is 1.5 times normal and their alkaline phosphatase and SGOT levels are more than 3 times normal
Patients with melanoma
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of fatigue severity. Timepoint: Weeks 0, 1, 2, 3, 4, 5 and 6. Method of measurement: Questionnaire (Cancer-Related Fatigue Scale).
- Secondary Outcome Measures
Name Time Method